Eficacia combinada de ivermectina y triclabendazol sobre fasciolosis en bovinos

This study aimed to evaluate the combined efficacy of triclabendazole (TCBZ) and ivermectin (IVM) against Fasciola hepatica in dairy cattle. Four groups of 15 Holstein cattle were formed: the first was the control (T0); TCBZ (12 mg/kg b.w.) was administered orally in the second (T1); TCBZ, fenbendazole and IVM (12, 10 and 0.2 mg/kg b.w.) were administered orally in the third (T2); and TCBZ (12 mg/kg b.w.) was administered orally and IVM (0.2 mg/kg b.w.) was administered subcutaneously in the fourth group (T3). The efficacy observed was 51.75 % (95 % CI: 42.41 - 61.09) in T1, 56.64 % (95 % CI: 47.42 - 65.86) in T2 and 69.93 % (95 % CI: 61.40 - 78.46) in T3. IVM increased the efficacy of TCBZ by 9.45 % in T2 and 35.13 % in T3 compared to T1. Although the addition of IVM, whether administered orally or subcutaneously, enhanced the efficacy of TCBZ, this combination as a pharmacological control strategy for F. hepatica in dairy cattle in Cajamarca was not encouraging.